Associated Papers
EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M et al.
Molecular Oncology, 2023
Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J et al.
Journal of Cellular Biochemistry, 2019
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
27780853 (PubMed )
Supplement: 10780432ccr160569-sup-163226_2_supp_3574910_tdyq9n.pdf
Select a paper to view details